Financhill
Back

Sarepta Therapeutics Quote, Financials, Valuation and Earnings

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!
Sell
31

SRPT
Sarepta Therapeutics

Last Price:
124.92
Seasonality Move:
11.13%

7 Day Trial

ALL ACCESS PASS

$ 7

U.S. Government Report Alert Tuesday

Discover the Secret Loophole

Sarepta Therapeutics Price Quote

$124.92
-0.09 (1.5%)
(Updated: November 6, 2024 at 5:27 AM ET)

Sarepta Therapeutics Key Stats

Sell
31
Sarepta Therapeutics (SRPT) is a Sell

Day range:
$121.18 - $125.25
52-week range:
$75.85 - $173.25
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
8.12
P/B ratio:
11.07%

Volume:
825.6K
Avg. volume:
793.8K
1-year change:
60.25%
Market cap:
$11.9B
Revenue:
$1.2B
EPS:
$0.74

How Much Does Sarepta Therapeutics Make?

Is Sarepta Therapeutics Growing As A Company?

  • What Is Sarepta Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.39%
  • What Is Sarepta Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Sarepta Therapeutics Stock Price Performance

What Is Sarepta Therapeutics 52-Week High & Low?

Sarepta Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sarepta Therapeutics?

Is Sarepta Therapeutics Cash Flow Positive?

  • What Is SRPT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$396.5M
  • What Is Sarepta Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $79.4M
  • What Is Sarepta Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$154.7M

Sarepta Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SRPT return on invested capital is 2.24%
  • What Is Sarepta Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 1.46%
  • What Is SRPT Return On Equity?
    ROE is a measure of profitability and is 5.37%

Sarepta Therapeutics Earnings Date & Stock Price

Sarepta Therapeutics Competitors

Sarepta Therapeutics Dividend Yield

Sarepta Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -5.47%
Revenue: 38.93% -6.3%

Analyst Recommendations

Buy Recommendations: 12
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 189.91
Upside from Last Price: 51.92%

Major Shareholders

  • How many SRPT shares are owned by institutional investors?
    147.7M SRPT shares are owned by institutional investors
  • How many SRPT shares are owned by insiders?
    15.5M SRPT shares are owned by insiders